The use of GLP-1 receptor agonists has been associated with a lower risk of developing several obesity-related cancers, according to a recent retrospective analysis of electronic health records. The study, led by Nathan Berger, MD, of Case Western Reserve University in Cleveland, delved into the potential impact of GLP-1s on cancer prevention among individuals with type II diabetes.
The findings revealed significant risk reductions for various cancers among individuals treated with GLP-1 receptor agonists compared to those treated with insulin. Some of the notable reductions included in gallbladder cancer, meningioma, pancreatic cancer, hepatocellular carcinoma, ovarian cancer, colorectal cancer, and more. These results shed light on the potential pleiotropic effects of GLP-1 receptor agonists in preventing obesity-associated cancers.
Notable Findings and Trends
Interestingly, the study did not find a decrease in cancer risk associated with GLP-1 receptors compared to metformin, a commonly used diabetes medication. While GLP-1s showed a reduced risk for stomach cancer compared to insulin, the difference was not statistically significant. Additionally, GLP-1s did not appear to lower the risk of postmenopausal breast cancer or thyroid cancer. The researchers also observed a trend towards a lower risk for colorectal and gallbladder cancer when comparing GLP-1s to metformin.
One concerning finding was an increased risk of kidney cancer associated with GLP-1 treatment relative to metformin. This unexpected result highlights the need for continued monitoring of patients undergoing treatment with GLP-1 receptor agonists. While GLP-1s have direct effects on kidney function, the link to an increased risk of kidney cancer is not entirely clear and warrants further investigation.
The analysis was based on electronic health records of over 1.6 million U.S. patients with type 2 diabetes who were prescribed GLP-1 receptor agonists, insulins, or metformin between 2005 and 2018. However, the study population primarily consisted of individuals with a higher prevalence of family history of cancer, obesity or overweight, and prior cancer screening. Therefore, the results may not be generalizable to other populations. Additionally, the analysis did not account for healthcare utilization or insurance type, which could impact the observed outcomes.
The study provides valuable insights into the potential benefits of GLP-1 receptor agonists in reducing the risk of obesity-associated cancers among individuals with type II diabetes. While the results are promising in terms of cancer prevention, the increased risk of kidney cancer associated with GLP-1 treatment warrants further investigation and monitoring of patients. The findings underscore the importance of continued research into the effects of GLP-1 receptor agonists on cancer prevention and management.
Leave a Reply